Research programme: BET inhibitors - Zenith Epigenetics Corp

Drug Profile

Research programme: BET inhibitors - Zenith Epigenetics Corp

Alternative Names: NexVas Autoimmune (AI) programme - Resverlogix; NexVas vascular inflammation; NexVas VI (vascular inflammation) therapy - Resverlogix; RVX-297

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Resverlogix Corporation; Zenith Epigenetics Corp
  • Developer Zenith Epigenetics Corp
  • Class Small molecules
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer
  • No development reported Autoimmune disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in Canada (PO)
  • 05 Jun 2017 Zenith Epigenetics has patent protection for its BET bromodomain inhibitors, in USA
  • 24 Sep 2014 Early research in Cancer in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top